ClinicalTrials.gg
Active, not recruitingNCT04483739IsKiaUpdated Jul 16, 2026

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

A Phase 3 interventional study of Carfilzomib Lenalidomide Dexamethasone and Isatuximab Carfilzomib Lenalidomide Dexamethasone in Multiple Myeloma, sponsored by European Myeloma Network B.V.. Active, not recruiting at 41 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by European Myeloma Network B.V. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Multiple Myeloma by European Myeloma Network B.V. — 3 open to participants now, 7 under way, 4 of them phase 3. Multiple Myeloma · European Myeloma Network B.V..

Enrollment
4th of 13
302 · median 117
Started
2020
the only one that year
Phase 3
4 of 14
1 open now
Registered
9th of 14
by date

Among the 14 studies in Multiple Myeloma by European Myeloma Network B.V., this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2020, is one of 4 in phase 3, and was the 9th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

3 of the 14 studies in Multiple Myeloma by European Myeloma Network B.V. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Multiple Myeloma by European Myeloma Network B.V., or all of them as a file.
02

Study summary

This protocol is a phase III study designed to compare the efficacy and the safety of Isa-KRd induction, transplant, Isa-KRd post ASCT consolidation and Isa-KRd light consolidation vs KRd induction, transplant, KRd post ASCT consolidation and KRd light consolidation After confirmation of eligibility criteria patients will be randomized to one of the 2 treatment groups in a 1:1 randomization ratio.

Read the detailed description

This is a open-label randomized phase III study that enrolls newly diagnosed MM patient eligible for high-dose chemotherapy and ASCT. Patients will be randomized at enrolment (1:1, stratification according to ISS Stage [3 levels: I vs II vs III] and cytogenetic risk FISH [2 levels: high-risk vs standard risk/missing] based on presence of t(4;14), t(14;16), and/or del 17p)) into 2 treatment arms: -ARM A: induction with 4 cycles of Isatuximab-Carfilzomib-Lenalidomide-dexamethasone (Isa-KRd) followed by cyclophophamide and stem cell collections, chemotherapy with Melphalan 200 mg/m2 followed by ASCT (Mel200-ASCT), 4 cycles of Isa-KRd post ASCT consolidation and 12 cycles of Isatuximab-Lenalidomide-Carfilzomib-dexamethasone (IsaKRd) light consolidation; ARM B: induction with 4 cycles of Carfilzomib-Lenalidomide-dexamethasone (KRd) followed by cyclophophamide and stem cell collections, chemotherapy with Melphalan 200 mg/m2 followed by ASCT (Mel200-ASCT), 4 cycles of KRd post ASCT consolidation and 12 cycles of Carfilzomib-Lenalidomide-dexamethasone (KRd) light consolidation. Details of all treatments (dose and schedule) are given in paragraph 8. After light consolidation patients are allowed to receive Lenalidomide maintenance as per standard of care.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • newly diagnosed MM
  • autologous stem cell transplantation
  • Isatuximab
  • Carfilzomib
  • Lenalidomide
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with newly diagnosed multiple myeloma and eligible to .
  • Patient is, in the investigator's opinion, willing and able to comply with the study visits and procedures required per protocol.
  • Patient has provided written in accordance with federal, local, and institutional guidelines prior to initiation of any study-specific activities or procedures. Subject does not have kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.
  • Monoclonal plasma cells in the bone marrow ≥10% or presence of a proven plasmacytoma and documented multiple myeloma satisfying at least one of the calcium, renal, anemia, bone (CRAB) criteria or biomarkers of criteria:
  • CRAB criteria:

    • Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than (ULN) or >2.75 mmol/L (>11 mg/dL)
    • Renal insufficiency: \<40mL/min or serum creatinine >177 μmol/L (>2 mg/dL)
    • Anemia: >2 g/dL below the lower limit of normal or hemoglobin \<10 g/dL
    • Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
  • Biomarkers of Malignancy:

    • Clonal bone marrow plasma cell percentage ≥60%
    • Involved: uninvolved serum FLC ratio ≥100
    • >1 focal lesion on magnetic resonance imaging (MRI) studies
  • Patient is 18 - 70 years old and is eligible for autologous stem cell transplantation
  • Patient has as defined by any one of the following:

    • Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or
    • Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin FLC ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.
  • ≥ 3 months
  • status ≤2
  • Clinical laboratory values meeting the following criteria during the Screening Phase:

    • Adequate hepatic function, with serum () ALT ≤ 2.5 times the upper limit of normal (ULN), AST (aspartate transaminase) ≤ 2.5 x the ULN
    • Serum direct ≤ 1.5 ULN) (except in subjects with congenital bilirubinemia, such as Gilbert syndrome, direct bilirubinemia ≤ 1.5 ULN)
    • (ANC) ≥ 1.0 × 109/L
    • count ≥ 75× 109/L (≥ 50× 109/L if myeloma involvement in the bone marrow is > 50%) and no platelet infusion in the 1 week prior to screening platelet count
    • Creatinine clearance (CrCl) ≥ 30 mL/minute. Creatinine clearance should be calculated using (Modified Diet in Renal Disese [MDRD])
    • Corrected serum calcium ≤ 13.5 mg/dL (3.4 mmol/L)
    • ≥ 40%. 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available.
  • Females of (FCBP)* complies with the conditions of the Pregnancy Prevention Plan, including confirmation that she has an adequate level of understanding and must agree to ongoing pregnancy testing and to practice or true abstinence. FCBP must use a highly effective and an additional barrier contraception method simultaneously for 4 weeks before starting therapy, during treatment and dose interruptions and for 5 months after the last dose of study drugs.
  • Male subjects must agree to practice contraception if sexually active with FCBP during the treatment and for 5 months after the last dose of study drugs. Males must agree to refrain from donating sperm for at least 90 days after the last dose of carfilzomib and for at least 5 months after the last dose of isatuximab.
  • *Note 1: a FCBP is a woman who:
  • has achieved menarche at some time point,
  • has not undergone a hysterectomy or bilateral oophorectomy or,
  • has not been naturally (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).
  • Note 2: true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with anti-myeloma therapy (does not include radiotherapy, biphosphonates, or a single short course of ≤ to the equivalent of dexamethasone 40 mg/day for 4 days).
  • Patients with non-secretory MM unless serum free light chains are present and the ratio is abnormal or a plasmacytoma with minimum largest diameters of > 2 cm.
  • Patients with plasma cell leukemia, amyloidosis, Waldenstrom Disease, POEMS syndrome
  • Meningeal involvement of multiple myeloma
  • Patient ineligible for transplantation
  • Pregnant or lactating females
  • Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization
  • Known infection (HIV)
  • Active hepatitis A, B or C infection. infection (subjects with hepatitis C that achieve a sustained virologic response after antiviral therapy are allowed), or infection (subjects with hepatitis B surface antigen or core antibody that achieve sustained virologic response with antiviral therapy are allowed). Tests to be performed if required per local country regulations. In fact it is not possible to avoid the risk of virological reactivation with the study treatments.
  • Unstable angina or myocardial infarction within 4 months prior to randomization, Class III or IV heart failure, uncontrolled angina, uncontrolled hypertension, (Uncontrolled hypertension, defined as an average systolic blood pressure ≥ 160 mmHg or diastolic ≥ 100 mmHg despite optimal treatment (measured following European Society of Hypertension/European Society of Cardiology 2013 guidelines), pulmonary embolia, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker
  • Non-hematologic within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
  • Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomization as defined by National Cancer Institute Common Toxicity Criteria () 5.0
  • Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib) and to PS80; prior to sucrose, histidine (as base and hydrochloride salt), or any of the components (active substance or ) of study treatments that are not amenable to premedication with steroids, or H2 blockers, that would prohibit further treatment with these agents.
  • to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
  • Any other medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give
  • Pregnant or breastfeeding woman or woman who intends to become pregnant during the participation in the study. FCBP unwilling to prevent pregnancy by the use of 2 reliable methods of for ≥4 weeks before the start of study treatment, during treatment (including dose interruptions), and for at least 28 days following discontinuation of study lenalidomide, or 30 days following discontinuation of carfilzomib or for 5 months after discontinuation of isatuximab treatment, whichever occurs last,
  • Male participants who disagree to practice true abstinence or disagree to use a condom during sexual contact with a pregnant woman or a FCBP while participating in the study, during dose interruptions, and for at least 28 days following discontinuation of study lenalidomide, or 30 days following discontinuation of carfilzomib, or for 5 months after discontinuation of isatuximab treatment, whichever occurs last, even if he has undergone a successful vasectomy.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    Krd Induction

    4 28 day cycles of Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22

    Drug: Carfilzomib Lenalidomide Dexamethasone

  • Experimental
    Isa-KRd induction

    Isatuximab= 10 mg/kg IV on day 1, 8, 15, and 22 during Cycle 1, followed by 10 mg/kg IV on days 1 and 15 during Cycles 2 to 4. Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22

    Drug: Isatuximab Carfilzomib Lenalidomide Dexamethasone

  • Experimental
    KRd post ASCT consolidation

    4 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22

    Drug: Carfilzomib Lenalidomide Dexamethasone

  • Experimental
    Isa-KRd post ASCT consolidation:

    4 28 day cycles of Isatuximab= 10 mg/kg IV on days 1 and 15 on cycles 5-8 Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22

    Drug: Isatuximab Carfilzomib Lenalidomide Dexamethasone

  • Experimental
    KRd light consolidation

    12 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15

    Drug: Carfilzomib Lenalidomide Dexamethasone

  • Experimental
    Isa-KRd light consolidation

    Isatuximab= 10 mg/kg IV on day 1 Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15

    Drug: Isatuximab Carfilzomib Lenalidomide Dexamethasone

Interventions

  • DrugCarfilzomib Lenalidomide Dexamethasone

    Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation

    Also known as: KRd

  • DrugIsatuximab Carfilzomib Lenalidomide Dexamethasone

    Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation

    Also known as: Isa-KRD

06

What researchers measure

Primary outcomes

  1. Rate of MRD negativity after ASCT consolidation treatment by NGS

    The rate of MRD negativity is determined as the proportion of patients with MRD negativity (≥10-5 sensitivity level) after ASCT consolidation treatment using ITT principle. For patients who withdraw from the study or are lost to follow up before four post ASCT consolidation cycles, the best MRD assessment will be considered. Patients will be classified as MRD positive if they have only MRD positive test results or do not undergo MRD assessment.

    Time frame: The end of consolidation, average of 12 months

Secondary outcomes

  1. Post induction MRD negativity rate by NGS

    The rate of MRD negativity after induction is determined as the proportion of patients with MRD negativity (≥10-5 sensitivity level, NGS) after the induction phase using ITT principle. Patients will be classified as MRD positive if they have only MRD positive test results or do not undergo MRD assessment/sample not adequate.

    Time frame: The end of induction, average of 4 months

  2. Progression-free survival (PFS) in the 2 arms

    PFS will be measured from the date of randomization to the date of first observation of PD, or death from any cause as an event. Subjects who have not progressed or who withdraw from the study will be censored at the time of the last complete disease assessment. All subjects who were lost to FU will also be censored at the time of last complete disease assessment

    Time frame: approximately up to 5 years

  3. Post light-consolidation MRD negativity rate by NGS

    The rate of MRD negativity after light consolidation is determined as the proportion of patients with MRD negativity (≥10-5 sensitivity level, NGS) after light consolidation phase using ITT principle. Patients will be classified as MRD positive if they have only MRD positive test results or do not undergo MRD assessment/sample not adequate. Patients who withdraw from the study or are lost to follow up before MRD evaluation, the best MRD assessment will be considered

    Time frame: At the end of light-consolidation, average of 24 months

  4. Overall Response Rate (ORR) post-induction

    Response rate (sCR, CR, VGPR, PR, ORR) will be evaluated according to IMWG Response criteria after induction.

    Time frame: Approx 4 months

  5. Overall Response Rate (ORR) post-transplant

    Response rate (sCR, CR, VGPR, PR, ORR) will be evaluated according to IMWG Response criteria after ASCT.

    Time frame: Approximately 8 months

  6. Overall Response Rate (ORR) post-consolidation

    Response rate (sCR, CR, VGPR, PR, ORR) will be evaluated according to IMWG Response criteria after consolidation.

    Time frame: Approximately 12 months

  7. Overall Response Rate (ORR) post light-consolidation

    Response rate (sCR, CR, VGPR, PR, ORR) will be evaluated according to IMWG Response criteria after light consolidation.

    Time frame: Approximately 24 months

  8. Post ASCT MRD negativity rate by NGS

    The rate of MRD negativity after ASCT is determined as the proportion of patients with MRD negativity (≥10-5 sensitivity level), NGS using ITT principle. For patients who withdraw from the study or are lost to follow up before ASCT, the best MRD assessment will be considered. Patients will be classified as MRD positive if they have only MRD positive test results or do not undergo MRD assessment.

    Time frame: After ASCT, approximately 8 months.

  9. MRD negativity rate by NGF post induction

    The rate of MRD negativity (by NGF) after induction is determined as the proportion of patients with MRD negativity (≥10-5 sensitivity level) after the specific phase using ITT principle. Patients will be classified as MRD positive if they have only MRD positive test results or do not undergo MRD assessment. Patients who withdraw from the study or are lost to follow up before MRD evaluation phase, the best MRD assessment will be considered.

    Time frame: Approximately 4 months

  10. MRD negativity rate by NGF post induction

    The rate of MRD negativity (by NGF) after ASCT is determined as the proportion of patients with MRD negativity (≥10-5 sensitivity level) after the specific phase using ITT principle. Patients will be classified as MRD positive if they have only MRD positive test results or do not undergo MRD assessment. Patients who withdraw from the study or are lost to follow up before MRD evaluation phase, the best MRD assessment will be considered.

    Time frame: Approximately 8 months

  11. MRD negativity rate by NGF post consolidation

    The rate of MRD negativity (by NGF) after consolidation is determined as the proportion of patients with MRD negativity (≥10-5 sensitivity level) after the specific phase using ITT principle. Patients will be classified as MRD positive if they have only MRD positive test results or do not undergo MRD assessment. Patients who withdraw from the study or are lost to follow up before MRD evaluation phase, the best MRD assessment will be considered.

    Time frame: Approximately 8 months

  12. MRD negativity rate by NGF post light consolidation

    The rate of MRD negativity (by NGF) after light consolidation are determined as the proportion of patients with MRD negativity (≥10-5 sensitivity level) after the specific phase using ITT principle. Patients will be classified as MRD positive if they have only MRD positive test results or do not undergo MRD assessment. Patients who withdraw from the study or are lost to follow up before MRD evaluation phase, the best MRD assessment will be considered.

    Time frame: Approximately 24 months

  13. Duration of response

    Duration of response is defined as the time between first documentation of response (achievement of at least a PR) and PD with deaths owning to causes other than progression not counted, but censored. Responders without disease progression at the cut-off date of final analysis will be censored either at the time of lost to FU, at the time of death due to other cause than PD, or at the at the time of last contact

    Time frame: approximately up to 9 years

  14. Duration of MRD negativity (by NGS and NGF)

    The duration of MRD Negativity (by NGS and NGF) is defined as time between first MRD Negativity and first MRD positivity. Patients without MRD positivity will be censored at last complete assessment

    Time frame: approximately up to 9 years

  15. Determine the rate of sustained for 1-year MRD negativity (by NGF and NGS) from post ASCT consolidation to post light consolidation

    Rate of 1 year sustained MRD negativity by NGS (from post ASCT consolidation to post light consolidation) will be also evaluated.

    Time frame: approximately up to 9 years

  16. Determine the time to progression (TTP)

    From the date of randomization to the date of first disease progression or death per PD, whichever occurs first

    Time frame: approximately up to 9 years

  17. Overall Survival (OS)

    Overall Survival (OS), measured from the date of from randomization to the date the subject's death

    Time frame: approximately up to 9 years

  18. Time to next therapy (TNT)

    TNT will be measured from the date of randomization to the date of next anti-myeloma therapy. Death due to any cause before starting therapy will be considered an event. Subjects who have not progressed or who withdraw from the study will be censored at the time of the last complete disease assessment. Subjects lost to FU will also be censored at the time of last contact.

    Time frame: approximately up to 9 years

  19. Progression-free survival on the next line of therapy (PFS2)

    Progression-free survival on the next line of therapy (PFS2) is defined as the time from randomization to progression on the next line of treatment or death, whichever comes first.

    Time frame: approximately up to 9 years

07

Study locations

41 sites
  • Het Ziekenhuisnetwerk Antwerpen - Department of Hematology
    Antwerp, Belgium
  • Fakultni Nemocnice Brno - Internal Hematology and Oncology Clinic
    Brno, Czechia
  • Fakultni Nemocnice Hradec Kralove - 4th Department of Internal Medicine
    Nový Hradec Králové, Czechia
  • Fakultni Nemocnice Ostrava - Department of Haematooncology
    Ostrava, Czechia
  • Vseobecna Fakultni Nemocnice V Praze - Internal Medicine, Hematology Clinic
    Prague, Czechia
  • Medical Center - University Of Freiburg - Department Innere Medizin Klinik für Innere Medizin I
    Freiburg im Breisgau, Germany
  • University Medical Center Hamburg-Eppendorf - Medizinische Klinik und Polikllinik Onkologie und Knochenmarktransplantation, Haematologie
    Hamburg, Germany
  • Klinikum rechts der Isar der TU Muenchen AöR - Innere Medizin III-Haematologie/Onkologie
    München, Germany
  • Alexandra Hospital - Department of Clinical Therapeutics National & Kapodistrian University of Athens School of Medicine
    Athens, Greece
  • Theageneio General Hospital - Department of Hematology Oncology
    Thessaloniki, Greece
  • Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G Salesi-SOD Clinica Ematologica
    Ancona, Italy
  • University Hospital Consorziale Policlinico-U.O. di Ematologia con Trapianto
    Bari, Italy
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico - U.O. di Ematologia
    Bologna, Italy
  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia - UOC Ematologia
    Brescia, Italy
  • Azienda Ospedaliera Santa Croce E Carle - S.C. Ematologia
    Cuneo, Italy
  • Careggi University Hospital - SOD Ematologia
    Florence, Italy
  • Azienda Ospedaliero-Universitaria Maggiore Della Carita - SDCU Ematologia
    Novara, Italy
  • Fondazione IRCCS Policlinico San Matteo-UOC Ematologia 1
    Pavia, Italy
  • Azienda Sanitaria Locale Di Pescara - U.O. Ematologia
    Pescara, Italy
  • A.O.U. Città della Salute e della Scienza di Torino-U.O. Ematologia
    Torino, Italy
  • Azienda Sanitaria Universitaria Giuliano Isontina-SC U.O.C Ematologia
    Trieste, Italy
  • Noordwest Ziekenhuisgroep Stichting - Internal Medicine - Hematology
    Alkmaar, Netherlands
  • Meander Medisch Centrum -Internal Medicine - Hematology
    Amersfoort, Netherlands
  • Amsterdam-Vrije Universiteit Medical Center (VUMC)
    Amsterdam, Netherlands
  • Amphia Hospital-Internal Medicine - Hematology
    Breda, Netherlands
  • Albert Schweitzerplaats 25
    Dordrecht, Netherlands
  • Zuyderland Medisch Centrum Stichting - Internal Medicine - Hematology
    Geleen, Netherlands
  • Universitair Medisch Centrum Groningen-Department of Haematology
    Groningen, Netherlands
  • Medisch Centrum Leeuwarden B.V. - Oncologisch Centrum Leeuwarden (OCL) and Internal Medicine - Hematology
    Leeuwarden, Netherlands
  • Sint Antonius Ziekenhuis Stichting-Internal Medicine - Hematology
    Nieuwegein, Netherlands
  • ErasmusMC, Rotterdam-Department of Hematology
    Rotterdam, Netherlands
  • Haga Hospital - Internal Medicine - Hematology
    s-Gravenweg, Netherlands
  • Oslo University Hospital HF - Oslo myelomatosesenter
    Oslo, Norway
  • St. Olavs Hospital HF - Department of Hematology
    Trondheim, Norway
  • Hospital Germans Trias I Pujol - Hematology Service ICO Badalona Clinic
    Badalona, Spain
  • Hospital Clinic De Barcelona - Myeloma and Amyloidosis Unit
    Barcelona, Spain
  • Hospital Universitario 12 De Octubre - Hematology
    Madrid, Spain
  • Hospital Universitario 12 De Octubre -Hematology and Hemotherapy Service
    Madrid, Spain
  • Clinica Universidad De Navarra - Central Clinical Trials Unit
    Pamplona, Spain
  • Hospital Universitario De Salamanca-Department of Hematology of the Salamanca University Care Complex
    Salamanca, Spain
  • Hospital Universitario Marques De Valdecilla -Hematology and Hemotherapy Service
    Santander, Spain
08

References and documents

Publications

  • Gay F, Roeloffzen W, Dimopoulos MA, Rosinol L, van der Klift M, Mina R, Oriol A, Katodritou E, Wu KL, Rodriguez Otero P, Hajek R, Antonioli E, van Duin M, D'Agostino M, Martinez-Lopez J, van Leeuwen-Segarceanu EM, Zamagni E, van de Donk NWCJ, Weisel KC, Pour L, Radocha J, Belotti A, Schjesvold F, Blade J, Einsele H, Sonneveld P, Boccadoro M, Broijl A. Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial. Nat Med. 2026 May;32(5):1773-1782. doi: 10.1038/s41591-026-04282-0. Epub 2026 Apr 6. PubMed 41942646 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jul 2025, 58 months.

Of 72 non-industry phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 108. This study's 58 months is below that.

Counting every sponsor, half of 181 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jul 23, 2020
StartActual
Sep 25, 2020
Primary completionActual
Jul 31, 2025
CompletionEst.
Dec 31, 2032
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04483739
Lead sponsor
European Myeloma Network B.V.
Collaborators
EMN Trial Office S.r.l. Impresa Sociale, Sanofi, Amgen
Responsible party
Sponsor
First posted
Jul 23, 2020
Start date
Sep 25, 2020
Primary completion
Jul 31, 2025
Completion
Dec 31, 2032 (estimated)
Last update
Jul 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion